{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:32:30Z","timestamp":1791948750302,"version":"4.3.4"},"reference-count":67,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS\/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS\/MPN was established involving 3 independent academic MDS\/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.<\/jats:p>","DOI":"10.1182\/blood-2014-10-607341","type":"journal-article","created":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T21:53:03Z","timestamp":1422309183000},"page":"1857-1865","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":187,"title":["An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults"],"prefix":"10.1182","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5504","authenticated-orcid":false,"given":"Michael R.","family":"Savona","sequence":"first","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center\/Vanderbilt University Medical Center, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon V.","family":"Tiu","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq I.","family":"Mughal","sequence":"additional","affiliation":[{"name":"Tufts University Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris Diderot, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Solary","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Tibes","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Center, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris Diderot, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Center, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Assistance Publique \u2013 H\u00f4pitaux de Paris, Universit\u00e9 Paris Diderot, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Gerds","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Politecnico La Fe, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.","family":"Niemeyer","sequence":"additional","affiliation":[{"name":"University of Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[{"name":"The August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"University of D\u00fcsseldorf, D\u00fcsseldorf, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"University of Southampton and Wessex Regional Genetics Laboratory, Salisbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2019111819162321000_B1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2019111819162321000_B2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111819162321000_B3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1309\/AJCPJ71PTVIKGEVT","article-title":"Myelodysplastic\/myeloproliferative neoplasms.","volume":"132","author":"Foucar","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"2019111819162321000_B4","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk Res"},{"key":"2019111819162321000_B5","article-title":"Myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN): an international perspective and recommendations on molecular pathogenesis and clinical characterization.","author":"Mughal","journal-title":"Haematologica"},{"issue":"2","key":"2019111819162321000_B6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease.","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"issue":"5","key":"2019111819162321000_B7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111819162321000_B8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111819162321000_B9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111819162321000_B10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2019111819162321000_B11","article-title":"Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis.","volume":"31","author":"Kvasnicka","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111819162321000_B12","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2014.04.012","article-title":"Are we altering the natural history of primary myelofibrosis?","volume":"38","author":"Savona","year":"2014","journal-title":"Leuk Res"},{"issue":"2","key":"2019111819162321000_B13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111819162321000_B14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"33","key":"2019111819162321000_B15","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [published correction appears in J Clin Oncol. 2012;30(36):4590].","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111819162321000_B16","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2019111819162321000_B17","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1002\/cncr.26741","article-title":"A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) or primary myelofibrosis (PMF).","volume":"118","author":"Bejanyan","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"2019111819162321000_B18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2013.084020","article-title":"Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.","volume":"98","author":"Onida","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2019111819162321000_B19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2007.10.015","article-title":"Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.","volume":"32","author":"Steensma","year":"2008","journal-title":"Leuk Res"},{"issue":"6","key":"2019111819162321000_B20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"15","key":"2019111819162321000_B21","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111819162321000_B22","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111819162321000_B23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111819162321000_B24","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2012-07-446849","article-title":"Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.","volume":"120","author":"Benjamini","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111819162321000_B25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pbc.20644","article-title":"Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.","volume":"46","author":"Lauchle","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2019111819162321000_B26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2007.06958.x","article-title":"Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.","volume":"140","author":"Niemeyer","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111819162321000_B27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"issue":"1","key":"2019111819162321000_B28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3324\/haematol.2014.109892","article-title":"Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.","volume":"100","author":"Niemeyer","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"2019111819162321000_B29","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2019111819162321000_B30","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias.","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2019111819162321000_B31","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111819162321000_B32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies.","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"issue":"19","key":"2019111819162321000_B33","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111819162321000_B34","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111819162321000_B35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"2019111819162321000_B36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","article-title":"SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"issue":"17","key":"2019111819162321000_B37","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms.","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111819162321000_B38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML\u2014dysplastic versus proliferative type.","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"issue":"7","key":"2019111819162321000_B39","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML).","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2019111819162321000_B40","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0145-2126(02)00021-8","article-title":"Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center.","volume":"26","author":"Gonz\u00e1lez-Medina","year":"2002","journal-title":"Leuk Res"},{"issue":"6","key":"2019111819162321000_B41","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2019111819162321000_B42","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes.","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111819162321000_B43","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia.","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111819162321000_B44","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"7","key":"2019111819162321000_B45","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes [published correction appears in Leukemia. 2013;27(10):2112].","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"2019111819162321000_B46","author":"Liu"},{"issue":"9","key":"2019111819162321000_B47","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111819162321000_B48","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111819162321000_B49","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111819162321000_B50","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111819162321000_B51","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111819162321000_B52","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111819162321000_B53","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"17","key":"2019111819162321000_B54","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2010-07-295857","article-title":"Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.","volume":"117","author":"Tiu","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111819162321000_B55","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","article-title":"Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms.","volume":"119","author":"Score","year":"2012","journal-title":"Blood"},{"issue":"25","key":"2019111819162321000_B56","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms.","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111819162321000_B57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2012.064048","article-title":"Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.","volume":"98","author":"Kar","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"2019111819162321000_B58","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111819162321000_B59","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2009-06-226340","article-title":"Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.","volume":"115","author":"Muramatsu","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111819162321000_B60","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"2019111819162321000_B61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2010.08196.x","article-title":"Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.","volume":"150","author":"Sugimoto","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111819162321000_B62","author":"Jeromin"},{"issue":"8","key":"2019111819162321000_B63","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.leukres.2010.02.033","article-title":"Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.","volume":"34","author":"Szpurka","year":"2010","journal-title":"Leuk Res"},{"issue":"7","key":"2019111819162321000_B64","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111819162321000_B65","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111819162321000_B66","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111819162321000_B67","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity.","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/12\/1857\/1382981\/1857.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/12\/1857\/1382981\/1857.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T16:57:01Z","timestamp":1717693021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/12\/1857\/33697\/An-international-consortium-proposal-of-uniform"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,3,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-10-607341","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}